Search Results - "Kresken, M."

Temocillin susceptibility in Enterobacterales with an ESBL/AmpC phenotype by Kresken, M., Pfeifer, Y., Werner, G.

Get full text

Molecular epidemiology of Acinetobacter baumannii and Acinetobacter nosocomialis in Germany over a 5-year period (2005–2009) by Schleicher, X., Higgins, P.G., Wisplinghoff, H., Körber-Irrgang, B., Kresken, M., Seifert, H.

“…To investigate the species distribution within the Acinetobacter calcoaceticus–Acinetobacter baumannii complex and the molecular epidemiology of A. baumannii…”
Get full text

Comparative in vitro activity of oral antimicrobial agents against Enterobacteriaceae from patients with community-acquired urinary tract infections in three European countries by Kresken, M., Körber-Irrgang, B., Biedenbach, D.J., Batista, N., Besard, V., Cantón, R., García-Castillo, M., Kalka-Moll, W., Pascual, A., Schwarz, R., Van Meensel, B., Wisplinghoff, H., Seifert, H.

“…Enterobacteriaceae causing community-acquired urinary tract infections were examined in selected outpatient clinics and hospitals in Belgium, Germany and Spain…”
Get full text

Antimicrobial susceptibility of bacterial isolates from patients presenting with ear, nose and throat (ENT) infections in the German community healthcare setting by Olzowy, B., Kresken, M., Havel, M., Hafner, D., Körber-Irrgang, B.

“…Empiric initial antibiotic therapy of bacterial infections is based primarily upon the susceptibility of the most common causative pathogens. The purpose of…”
Get full text

Multiresistant pathogens--a challenge for clinicians by Lode, H M, Stahlmann, R, Kresken, M

“…Gram-negative pathogens are currently isolated frequently in invasive nosocomial infections and give rise to major therapeutic problems due to their resistance…”
Get more information

Resistance trends and in vitro activity of tigecycline and 17 other antimicrobial agents against Gram-positive and Gram-negative organisms, including multidrug-resistant pathogens, in Germany by Kresken, M., Becker, K., Seifert, H., Leitner, E., Körber-Irrgang, B., von Eiff, C., Löschmann, P.-A.

“…To document the development of resistance to tigecycline in comparison with 17 other antimicrobials, the susceptibilities of 2,741 isolates comprising 16…”
Get full text

Surveillance of antibiotic consumption : clarification of the "definition of data on the nature and extent of antibiotic consumption in hospitals according to § 23 paragraph 4 sentence 2 of the IfSG" by Schweickert, B, Kern, W V, de With, K, Meyer, E, Berner, R, Kresken, M, Fellhauer, M, Abele-Horn, M, Eckmanns, T

“…According to § 23 paragraph 4 of the German Infection Prevention Act (IfSG; July 2011), hospitals and clinics for ambulatory surgery are obliged to establish a…”
Get full text

Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations by BRAUERS, J, KRESKEN, M, MENKE, A, ORLAND, A, WEIHER, H, MORRISSEY, I

“…The bactericidal activities of daptomycin, vancomycin, teicoplanin and linezolid at human peak free serum concentrations (C(max,free)) were determined against…”
Get full text

Susceptibility of clinical isolates of frequently encountered bacterial species to tigecycline one year after the introduction of this new class of antibiotics: results of the second multicentre surveillance trial in Germany (G-TEST II, 2007) by Kresken, M., Leitner, E., Seifert, H., Peters, G., von Eiff, C.

“…Tigecycline, a broad-spectrum antibiotic for parenteral use, was introduced in Germany in May 2006. In the G-TEST-II trial, the susceptibility of isolates,…”
Get full text

P1830 Susceptibility of Gram-positive pathogens to daptomycin and other antimicrobial agents: first results from the DAPTOGERM Surveillance Study by Kresken, M, Brauers, J

Get full text

Susceptibility of common aerobic pathogens to tigecycline: results of a surveillance study in Germany by Kresken, M, Leitner, E, Brauers, J, Geiss, H. K, Halle, E, von Eiff, C, Peters, G, Seifert, H

“…Tigecycline is a novel antimicrobial agent for parenteral use encompassing a broad spectrum of bacterial pathogens, including multi-resistant organisms. Here,…”
Get full text

Activities of various β-lactams and β-lactam/β-lactamase inhibitor combinations against Acinetobacter baumannii and Acinetobacter DNA group 3 strains by Brauers, J., Frank, U., Kresken, M., Rodloff, A.C., Seifert, H.

“…Acinetobacter baumannii and Acinetobacter DNA group 3 are members of the so-called A. calcoaceticus–A. baumannii complex and are important nosocomial…”
Get full text

Comparative activity of pradofloxacin and marbofloxacin against coagulase‐positive staphylococci in a pharmacokinetic–pharmacodynamic model based on canine pharmacokinetics by KÖRBER‐IRRGANG, B, WETZSTEIN, H.‐G, BAGEL‐TRAH, S, HAFNER, D, KRESKEN, M

“…Körber‐Irrgang, B., Wetzstein, H.‐G., Bagel‐Trah, S., Hafner, D., Kresken, M. Comparative activity of pradofloxacin and marbofloxacin against…”
Get full text

Surveillance of linezolid resistance in Germany, 2001–2002 by Brauers, J., Kresken, M., Hafner, D., Shah, P.M.

“…A surveillance study was performed throughout Germany from November 2001 to June 2002 to assess the prevalence of linezolid-resistant isolates among…”
Get full text

Nationwide German Multicenter Study on Prevalence of Antibiotic Resistance in Staphylococcal Bloodstream Isolates and Comparative In Vitro Activities of Quinupristin-Dalfopristin by VON EIFF, C, REINERT, R. R, KRESKEN, M, BRAUERS, J, HAFNER, D, PETERS, G

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

S2k guidelines of the PEG on calculated parenteral initial treatment of bacterial diseases in adults : Focussed summary and supplementary information on antibiotic treatment of critically ill patients by Brinkmann, A, Röhr, A C, Frey, O R, Krüger, W A, Brenner, T, Richter, D C, Bodmann, K-F, Kresken, M, Grabein, B

“…In January 2018 the recent revision of the S2k guidelines on calculated parenteral initial treatment of bacterial diseases in adults-update 2018 (Editor: Paul…”
Get full text

P1811 In vitro activity of tigecycline against Gram-positive and Gram-negative bacteria cultured from blood samples, wound swabs and intra-abdominal specimens: results of the German T.E.S.T. Surveillance Program 2005 by Kresken, M, Brauers, J, Geiss, H, Halle, E, Leitner, E, Peters, G, Seifert, H

Get full text

P1831 Comparative in vitro activity of tigecycline against staphylococci and enterococci from patients on ICU-and non-ICU wards: results of the German T.E.S.T.Surveillance Program 2005 by Kresken, M, Brauers, J, Geiss, H, Halle, E, Leitner, E, Peters, G, Seifert, H

Get full text

P666 Comparative in vitro activity of tigecycline against ICU-and non-ICU isolates offive clinically important Gram-negative pathogens: results of the German T.E.S.T.Surveillance Programme 2005 by Kresken, M, Brauers, J, Geiss, H, Halle, E, Leitner, E, Peters, G, Seifert, H

Get full text

Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against S taphylococcus aureus , Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations by Brauers, J, Kresken, M, Menke, A, Orland, A, Weiher, H, Morrissey, I

“…Abstract The bactericidal activities of daptomycin, vancomycin, teicoplanin and linezolid at human peak free serum concentrations ( Cmax,free ) were determined…”
Get full text